Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$2.50 USD
-0.05 (-1.96%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $2.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ANIX 2.50 -0.05(-1.96%)
Will ANIX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ANIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANIX
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia
ANIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
Other News for ANIX
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024
7 Penny Biotech Stocks to Triple Your Investment
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences begins treating fifth patient in ovarian cancer CAR-T trial
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines